Remove Clinical Trials Remove Cultivation Remove DEA Remove History
article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.

DEA 104
article thumbnail

ASA offers solution to DOJ research block: Our comments on the DEA’s proposed rules

Americans for Safe Access

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA CBD Regulations Are On the Way (Sorta)

Canna Law Blog

A little CBD history. Until recently, CBD resided in a legal penumbra where hemp was still scheduled on the federal Controlled Substances Act and could not be cultivated without a permit from the Drug Enforcement Administration (“DEA”).

CBD 75
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history.